Cost Effectiveness of Universal Screening for HCV Infection in the Era of Direct-Acting, Pangenotypic Treatment Regimens

Most persons infected with hepatitis C virus (HCV) in the United States (US) were born from 1945 through 1965—testing is recommended for this cohort. However, HCV incidence is increasing among younger persons in many parts of the country and treatment is recommended for all adults with HCV infection. We aimed to estimate the cost effectiveness of universal 1-time screening for HCV infection in all adults living in the US and to determine the prevalence of HCV antibody above which HCV testing is cost-effective.

https://ift.tt/2NY6Nbt